OR WAIT null SECS
© 2023 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
MilliporeSigma’s €130 million (USD$132 million) investment is designed to increase manufacturing capacity of single-use assemblies.
MilliporeSigma, the US and Canada Life Science business of Merck KGaA, announced on Sept. 8, 2022, that it would be investing €130 million into its manufacturing plant in Molsheim, France. This investment is geared toward strengthening its manufacturing capabilities for single-use assemblies.
The expansion will increase capacity for the manufacturing of single-use assemblies belonging to MilliporeSigma’s Mobius portfolio.These additions include multiple 37,00 ft2 ISO7 clean rooms, an administrative building, and a new logistics warehouse, all of which are planned to be operational by the end of 2024 and at full production by 2028. The company estimates that this investment will create more than 800 jobs by the end of 2028.
“MilliporeSigma is determined to provide patients in Europe and worldwide with reliable access to vaccines and life-saving therapies,” said Belén Garijo, chair of the executive board and CEO, Merck KGaA, in a press release. “This investment in France is an integral component of our plans to expand our global manufacturing footprint and deliver superior customer value across the globe.”
“France is central to our strategy to drive long-term growth and expand our global leadership position in Life Science,” said Matthias Heinzel, member of the executive board of Merck KGaA, and CEO of Life Science. “In recent years, many biopharmaceutical manufacturers have turned to single-use technologies for their flexibility, cost savings, speed, and reduced contamination risk, leading to double-digit market growth for this segment. The Covid-19 pandemic has reinforced this trend. The investment will accelerate the delivery of critical products and technologies our customers need to bring breakthrough treatments to patients in need around the world.”